<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="10009">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02016105</url>
  </required_header>
  <id_info>
    <org_study_id>GP17-301</org_study_id>
    <secondary_id>2013-000747-11</secondary_id>
    <nct_id>NCT02016105</nct_id>
  </id_info>
  <brief_title>Study to Demonstrate Equivalent Efficacy and to Compare Safety of Biosimilar Adalimumab (GP2017) and Humira</brief_title>
  <acronym>ADACCESS</acronym>
  <official_title>A Randomized, Double-blind, Multicenter Study to Demonstrate Equivalent Efficacy and to Compare Safety and Immunogenicity of a Biosimilar Adalimumab (GP2017) and Humira® in Patients With Moderate to Severe Chronic Plaque-type Psoriasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sandoz</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sandoz</source>
  <oversight_info>
    <authority>Bulgaria: Bulgarian Drug Agency</authority>
    <authority>Germany: Paul-Ehrlich-Institut</authority>
    <authority>Hungary: National Institute for Quality and Organizational Development in Healthcare and Medicines</authority>
    <authority>Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products</authority>
    <authority>Romania: National Agency for Medicines and Medical Devices</authority>
    <authority>Russia: Ministry of Health of the Russian Federation</authority>
    <authority>Slovakia: State Institute for Drug Control</authority>
    <authority>United States: Food and Drug Administration</authority>
    <authority>India: Ministry of Health</authority>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <authority>Spain: Spanish Agency of Medicines</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to demonstrate equivalent efficacy and similarity in the safety
      profile of GP2017 and Humira® in patients with moderate to severe chronic plaque-type
      psoriasis.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">June 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>The primary outcome measure is the PASI 75 response rate</measure>
    <time_frame>Week 16</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>PASI response rates</measure>
    <time_frame>Weeks 1,3,5,7,9,11,13, 15,16,17</time_frame>
    <safety_issue>No</safety_issue>
    <description>PASI 50, 75, 90 and 100 will be assessed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in IGA</measure>
    <time_frame>Weeks 1, 3, 5, 7, 9, 11, 13, 15, 16 and 17</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient't health related quality of life (HRQoL)</measure>
    <time_frame>Week 11 and 16</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">448</enrollment>
  <condition>Plaque Type Psoriasis</condition>
  <arm_group>
    <arm_group_label>GP2017 Adalimumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Study arm with intervention being studied in the protocol.  Adalimumab Solution for subcutaneous injection with an initial dose of 80 mg s.c. in Week 0, followed by 40 mg s.c. eow, starting at Week 1 and ending at Week 33.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Humira ® Adalimumab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Humira® Adalimumab as a subcutaneous injection with an initial dose of 80 mg s.c. in Week 0, followed by 40 mg s.c. eow, starting at Week 1 and ending at Week 33.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GP2017 Adalimumab</intervention_name>
    <arm_group_label>GP2017 Adalimumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Humira ® Adalimumab</intervention_name>
    <arm_group_label>Humira ® Adalimumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men or women at least 18 years of age at time of screening

          -  Chronic plaque-type psoriasis diagnosed for at least 6 months before randomization

          -  Moderate to severe psoriasis as defined at baseline by:

               -  PASI score of 12 or greater

               -  Investigator´s Global Assessment score of 3 or greater (based on a scale of 0 -
                  4) and,

               -  Body Surface Area affected by plaque-type psoriasis of 10% or greater

          -  Chronic plaque-type psoriasis patients who have previously received phototherapy or
             systemic psoriasis therapy at least once or who are candidates for such therapies in
             the opinion of the investigator.

        Exclusion Criteria:

          -  Forms of psoriasis other than chronic plaque-type

          -  Drug-induced psoriasis

          -  Ongoing use of prohibited psoriasis treatments

          -  Previous exposure to adalimumab

          -  Active ongoing inflammatory diseases other than psoriasis that might confound the
             evaluation of the benefit of treatment with adalimumab

        Other In-/Exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Karsten Roth, Dr.</last_name>
    <phone>+498024476-0</phone>
  </overall_contact>
  <location>
    <facility>
      <name>SANARA s.r.o, Dermatovenerologicka Ambulancia</name>
      <address>
        <city>Svidnik</city>
        <zip>08901</zip>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Selenkova</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Slovakia</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>April 22, 2014</lastchanged_date>
  <firstreceived_date>December 14, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>plaque type psoriasis</keyword>
  <keyword>equivalent efficacy</keyword>
  <keyword>safety and immunogenicity</keyword>
  <keyword>GP2017</keyword>
  <keyword>Humira®</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Adalimumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
